Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome

التفاصيل البيبلوغرافية
العنوان: Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome
المؤلفون: Charlotte S. Roberts, James L. Tatum, Sarah E. Joyner, Joseph P. Ornato, Robert L. Jesse, F. Philip Anderson, Michael C. Kontos
المصدر: Mayo Clinic Proceedings. 82:551-555
بيانات النشر: Elsevier BV, 2007.
سنة النشر: 2007
مصطلحات موضوعية: Acute coronary syndrome, medicine.medical_specialty, medicine.diagnostic_test, business.industry, General Medicine, medicine.disease, Surgery, Coronary artery disease, chemistry.chemical_compound, chemistry, Internal medicine, Low-density lipoprotein, Angiography, medicine, lipids (amino acids, peptides, and proteins), Myocardial infarction, business, National Cholesterol Education Program, Dyslipidemia, Lipoprotein cholesterol
الوصف: OBJECTIVE To assess the ability of patients with an acute coronary syndrome (ACS) to meet the recommended low-density lipoprotein cholesterol (LDL-C) goal of 100 mg/dL and optional aggressive lowering to 70 mg/dL. PATIENTS AND METHODS Patients diagnosed as having ACS who had lipid levels measured within 24 hours of admission from January 1, 1998, through December 31, 2002, were assessed for the ability to meet the 2 target LDL-C levels. Patients were considered to have ACS if they were diagnosed as having myocardial infarction, had significant disease on angiography, or had a history of coronary artery disease. Patients were classified into 1 of 4 groups on the basis of the degree of LDL-C lowering required to meet the 2 different goals: less than 33%, 33% to 39%, 40% to 49%, and 50% or more. Patients with myocardial infarction who had lipid sampling performed more than 24 hours after admission were excluded. RESULTS The mean ± SD LDL-C level was 111±43 mg/dL in the 1322 patients who met criteria for ACS and had LDL-C levels assessed. On the basis of a target LDL-C value of less than 100 mg/dL, 43% of patients were at goal and did not require treatment, and only 2.5% had an LDL-C level that required a 50% or greater reduction to meet goal. In contrast, using the newer LDL-C target of 70 mg/dL, 85% patients required treatment, and 23% of patients required a 50% or greater decrease in LDL-C level and therefore were likely to require more than 1 lipid-lowering agent. CONCLUSION Decreasing the LDL-C target to less than 70 mg/dL substantially increases the number of patients with ACS who would require treatment. A significant proportion of patients will require a reduction in LDL-C level of 50% or more, which is not easily achievable with current lipid-lowering monotherapy.
تدمد: 0025-6196
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4f718b97b61c96230326153cf81cd89dTest
https://doi.org/10.4065/82.5.551Test
حقوق: CLOSED
رقم الانضمام: edsair.doi...........4f718b97b61c96230326153cf81cd89d
قاعدة البيانات: OpenAIRE